专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06616925B1 Combined preparation for the treatment of neoplasic diseases or of infectious diseases 失效
标题翻译：用于治疗新生儿疾病或感染性疾病的联合制剂
公开(公告)号：US06616925B1
公开(公告)日：2003-09-09
申请号：US09081443
申请日：1998-05-19
申请人： Jacques Bartholeyns , Yves Fouron , Jean-Loup Romet-Lemonne
发明人： Jacques Bartholeyns , Yves Fouron , Jean-Loup Romet-Lemonne
IPC分类号： A01N6300
CPC分类号： C12N5/0645 , A61K31/232 , A61K31/282 , A61K31/336 , A61K31/407 , A61K31/505 , A61K31/655 , A61K31/704 , A61K35/15 , A61K39/0011 , A61K45/06 , A61K2039/5154 , A61K2300/00
摘要： The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.
摘要翻译：本发明涉及包含作为活性物质的以下单独组分的组合制剂，其为成套工具：单核细胞来源的细胞，特别是细胞毒性巨噬细胞，化学疗法或免疫治疗药物，用于同时，分开或顺序使用，用于治疗癌症或传染病。

2. 发明授权

US06399372B1 Monocyte derived cells with immunostimulating properties, their preparation and uses 失效
标题翻译：单核细胞衍生细胞具有免疫刺激性质，其制备和用途
公开(公告)号：US06399372B1
公开(公告)日：2002-06-04
申请号：US09647534
申请日：2000-10-02
申请人： Jacques Bartholeyns , Mohamed Chokri , Nathalie Latour
发明人： Jacques Bartholeyns , Mohamed Chokri , Nathalie Latour
IPC分类号： C12N500
CPC分类号： C12N5/0645 , A61K38/00 , A61K2035/124 , C12N2510/00
摘要： The invention relates to stimulated monocyte derived cells presenting the following characteristics: 1) increased release, with respect to normal monocyte derived cells, of for instance PDGF (platelet derived growth factor), and increased presence, on their membranes, with respect to normal monocyte derived cells, of for instance CD1&agr;, and/or: 2) presence in their nucleus of at least one exogenous nucleic acid which has been integrated in the absence of the monocyte derived cell division. These stimulated monocyte derived cells can be the active substance of pharmaceutical compositions.
摘要翻译：本发明涉及具有以下特征的受刺激的单核细胞衍生细胞：1）相对于正常单核细胞来源的细胞，例如PDGF（血小板衍生生长因子）的释放增加，并且在其膜上相对于正常单核细胞增加的存在衍生的细胞，例如CD1α，和/或：2）在其核中存在已经在不存在单核细胞衍生的细胞分裂的情况下整合的至少一种外源核酸。这些刺激的单核细胞来源的细胞可以是药物组合物的活性物质。

3. 发明授权

US6051432A Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions 失效
标题翻译：巨噬细胞，其制备方法及其作为药物组合物的活性物质的用途
公开(公告)号：US6051432A
公开(公告)日：2000-04-18
申请号：US400875
申请日：1999-09-22
申请人： Mohamed Chokri , Jacques Bartholeyns
发明人： Mohamed Chokri , Jacques Bartholeyns
IPC分类号： A61K35/12 , C12N5/0786 , C12Q1/00 , G01N33/53
CPC分类号： C12N5/0645 , A61K2035/124 , C12N2500/38 , C12N2501/22 , C12N2501/24 , Y10S435/81
摘要： The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-.gamma. is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-.gamma. is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-.gamma. is in a ratio such that after 60 h of activation with IFN-.gamma., the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-.gamma. activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.
摘要翻译：本发明涉及具有以下性质中的至少一种的巨噬细胞：其相对于标准巨噬细胞而言，其IFN-γ的细胞毒性活性增加约20％至30％，优选为约70％; 其与IFN-γ的细胞毒活性相对于标准巨噬细胞增加约20至约40％，优选为约93％; 与IFN-γ的激活相应的细胞毒活性的失活的延长使得在用IFN-γ活化60小时后，细胞毒活性高于或等于30％，优选约55 与由IFN-γ激活引起的巨噬细胞呈现的最大细胞毒活性相比，所述细胞毒活性被测量为目标肿瘤细胞尤其是U937细胞3-H胸苷掺入的抑制百分比。

4. 发明授权

US5662899A Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions 失效
标题翻译：巨噬细胞，其制备方法及其作为药物组合物的活性物质的用途
公开(公告)号：US5662899A
公开(公告)日：1997-09-02
申请号：US374629
申请日：1995-01-17
申请人： Mohamed Chokri , Jacques Bartholeyns
发明人： Mohamed Chokri , Jacques Bartholeyns
IPC分类号： A61K35/12 , A61K35/15 , A61K35/17 , A61P35/00 , C07K16/46 , C12N5/0786 , C12P21/08 , C12N5/08 , A61K35/14 , A61K35/26 , A61K35/28
CPC分类号： A61K35/17 , A61K35/15 , C07K16/468 , C12N5/0645 , A61K2035/124 , C12N2500/38 , C12N2501/02 , C12N2501/22 , C12N2501/24
摘要： Macrophages have been developed, which possess at least one of the following properties:their cytotoxic activity without IFN-.gamma. is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%;their cytotoxic activity with IFN-.gamma. is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%;deactivation of the cytotoxic activity following activation of IFN-.gamma. is such that sixty hours after activation with IFN-.gamma., the residual cytotoxic activity is at least 30%, preferably about 55%, of the maximum cytotoxic activity presented by the macrophages due to IFN-.gamma. activation, with said cytotoxic activity being measured as a percentage of the inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells. The macrophages are prepared by culturing healthy human monocytes and lymphocytes in a culture medium containing 1,25-dihydroxy vitamin D.sub.3 and GM-CSF.
摘要翻译： PCT No.PCT / EP93 / 01232 Sec。 371日期1995年1月17日 102（e）日期1995年1月17日PCT提交1993年5月18日PCT公布。第WO94 / 26875号公报日期1994年11月24日已经开发了具有至少以下性质之一的巨噬细胞：相对于标准巨噬细胞，其IFN-γ的细胞毒性活性增加约20至30％，优选为约70％; 其与IFN-γ的细胞毒活性相对于标准巨噬细胞增加约20至约40％，优选为约93％; IFN-γ活化后细胞毒活性的失活使得用IFN-γ活化后的六十小时，剩余的细胞毒性活性是巨噬细胞由于IFN引起的最大细胞毒性活性的至少30％，优选约55％ - γ激活，所述细胞毒活性被测量为目标肿瘤细胞，特别是U 937细胞的3-H胸苷掺入的抑制百分比。通过在含有1,25-二羟基维生素D3和GM-CSF的培养基中培养健康的人单核细胞和淋巴细胞来制备巨噬细胞。

5. 发明申请

US20060068495A1 Process of cell electrofusion 审中-公开
标题翻译：细胞电融合过程
公开(公告)号：US20060068495A1
公开(公告)日：2006-03-30
申请号：US10504939
申请日：2003-02-21
申请人： Justin Tessie , Jacques Bartholeyns
发明人： Justin Tessie , Jacques Bartholeyns
IPC分类号： C12N15/01 , C12N15/87
CPC分类号： A61K41/00 , A61K39/001 , A61K2035/122 , A61K2039/5152 , A61K2039/5154 , C07K16/2896 , C12M35/02 , C12N5/16 , C12N13/00 , C12N2501/599 , C12N2501/90
摘要： The invention relates to the use of an electrical field applied to a mixture containing a first type of cell (C1), a second type of cell (C2), a bispecific ligand able to bind to C1 and/or to C2 and non-covalent complexes formed between C1, C2 and the bispecific ligand, for the preparation of a cell population enriched in C1-C2 heterohybrids or for the preparation of C1-C2 heterohybrids.
摘要翻译：本发明涉及应用于含有第一类型细胞（C1），第二类型细胞（C2），能够结合C1和/或C2并且非共价键的双特异性配体的混合物的电场的用途在C1，C2和双特异性配体之间形成的复合物，用于制备富含C1-C2杂合子的细胞群或用于制备C1-C2杂合子。

6. 发明授权

US06821516B1 Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions 失效
标题翻译：巨噬细胞，其制备方法及其作为药物组合物的活性物质的用途
公开(公告)号：US06821516B1
公开(公告)日：2004-11-23
申请号：US09304564
申请日：1999-05-04
申请人： Mohamed Chokri , Jacques Bartholeyns
发明人： Mohamed Chokri , Jacques Bartholeyns
IPC分类号： A61K39395
CPC分类号： C12N5/0645 , A61K2035/124 , C12N2500/38 , C12N2501/22 , C12N2501/24 , Y10S435/81
摘要： The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-&ggr; is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-&ggr; is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-&ggr; is in a ratio such that after 60h of activation with IFN-&ggr;, the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-&ggr; activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.
摘要翻译：本发明涉及具有以下性质中的至少一种的巨噬细胞：相对于标准巨噬细胞，其IFN-γ的细胞毒活性增加约20至30％，优选为约70％; 其与IFN-γ的细胞毒活性相对于标准巨噬细胞增加约20至约40％，优选为约93％; 与IFN-γ的激活相应的细胞毒活性的失活的延长是使得在用IFN-γ活化60小时后，细胞毒活性高于或等于30％，优选约55％，与由IFN-γ活化引起的巨噬细胞呈现的最大细胞毒活性相比，所述细胞毒活性被测量为目标肿瘤细胞，特别是U 937细胞的3-H胸苷掺入的抑制百分比。

7. 发明授权

US06737051B1 Cell compositions containing macrophages, presenting anti-infectious and hematopoietic properties 失效
标题翻译：含有巨噬细胞的细胞组合物，具有抗感染和造血特性
公开(公告)号：US06737051B1
公开(公告)日：2004-05-18
申请号：US09890652
申请日：2001-11-27
申请人： Bernard Klein , Zhao Yang Lu , Jacques Bartholeyns
发明人： Bernard Klein , Zhao Yang Lu , Jacques Bartholeyns
IPC分类号： A01N6300
CPC分类号： C12N5/0645 , A61K35/15 , A61K35/17 , C12N2501/22 , C12N2501/24 , A61K2300/00
摘要： The invention relates to a cell composition containing macrophages, presenting anti-infectious and hematopoietic properties. More particularly, the invention relates to a cell composition containing macrophages, myeloid cells and progenitors; said cell compositions are useful for the restoration of hematopoiesis in an aplasic patient and/or the protection of patients against infectious diseases or against residual tumors.
摘要翻译：本发明涉及含有巨噬细胞的细胞组合物，具有抗感染和造血特性。更具体地，本发明涉及含有巨噬细胞，骨髓细胞和祖细胞的细胞组合物; 所述细胞组合物可用于恢复一次性患者的造血作用和/或对患者免受感染性疾病或对于残留肿瘤的保护。

8. 发明申请

US20050048039A1 Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues 审中-公开
标题翻译：用扩散或难以接近细胞或组织治疗或诊断人类病理的方法
公开(公告)号：US20050048039A1
公开(公告)日：2005-03-03
申请号：US10766929
申请日：2004-01-30
申请人： Patrick Dreyfus , Elaine Parrish , Luis Garcia , Mohamed Chokri , Jacques Bartholeyns , Elise Peltekian
发明人： Patrick Dreyfus , Elaine Parrish , Luis Garcia , Mohamed Chokri , Jacques Bartholeyns , Elise Peltekian
IPC分类号： C12N15/09 , A61K35/14 , A61K38/00 , A61K48/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P19/08 , A61P21/00 , A61P25/00 , A61P25/02 , C12N5/0786 , C12N5/10 , G01N33/569 , G01N33/68
CPC分类号： C12N5/0645 , A61K38/00 , A61K48/00 , C12N2510/00 , G01N33/56972 , G01N33/6893 , G01N33/6896
摘要： Method for the treatment or diagnosis of pathologies either expressed in injured or pathological multiple sites in tissues or in the body or expressed in injured or pathological sites of tissues or cells in sites of the body, which are difficult to access, with said sites or areas in immediate proximity to said sites being the source of the release of chemotactic factors for endogenous macrophages, either spontaneously or upon suitable stimulation, wherein said treatment is carried out by administration to the body of an appropriate amount of exogenous monocyte derived cells, said monocyte derived cells being, in the case of treatment, loaded with corrective agents with respect to the pathologies to be treated, and with said monocyte derived cells having the properties of mobilisation towards the source of the above-said released chemotactic factors and in target the cells present in the vicinity of the said released chemotactic factors, and in the case of diagnosis, loaded with a marker enabling the detection of injured or pathological sites.
摘要翻译：用于治疗或诊断在组织或体内的损伤或病理多个部位中表达的病理学或在身体部位的组织或细胞的损伤或病理部位表达的病症，所述部位或部位难以进入所述部位或区域紧邻所述位点是内源性巨噬细胞的趋化因子释放的来源，或者是自发地或在适当的刺激下，其中所述的治疗通过向人体施用适量的外源性单核细胞来源的细胞来进行，所述单核细胞来源于在治疗的情况下，细胞相对于待治疗的病理物质加载校正剂，并且所述单核细胞衍生的细胞具有向上述释放的趋化因子的来源移动的性质，并且靶向存在的细胞在所述释放的趋化因子附近，并且在诊断的情况下装载标记呃能够检测受伤或病理部位。

9. 发明授权

US06703016B1 Apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines 失效
标题翻译：凋亡体，含有其的单核细胞衍生细胞，其制备方法及其作为疫苗的用途
公开(公告)号：US06703016B1
公开(公告)日：2004-03-09
申请号：US09700108
申请日：2000-12-28
申请人： Marc Gregoire , Jacques Bartholeyns
发明人： Marc Gregoire , Jacques Bartholeyns
IPC分类号： A61K4800
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/5154 , C12N2500/36
摘要： The present invention relates to apoptotic bodies derived from human tumor cells or cell lines recovered from patient's tumor biopsy and induced to apoptotis, said apoptotic bodies having the following characteristics: they maintain plasma membrane integrity, they are vesicles above about 0,1 &mgr;m, they contain intact mitochondria and cleaved nuclear DNA originating from the tumor cells, they present unmasked tumor antigens on their membranes, they present specific tumor and MHC antigens from the patient. The invention also provides new monocytes derived cells, which can be used as anti-tumor vaccines after integration of apoptotic bodies. Apoptotic bodies are phagocytosed and processed by monocyte derived antigen presenting cells and potentiate the effective tumor antigenic presentation to the immune system.
摘要翻译：本发明涉及源自人肿瘤细胞或从患者肿瘤活组织检查中诱导凋亡的细胞系的凋亡小体，所述凋亡小体具有以下特征：它们保持质膜完整性，它们是高于约0.1μm的囊泡，它们含有源自肿瘤细胞的完整的线粒体和切割的核DNA，它们在其膜上存在未被掩蔽的肿瘤抗原，它们呈现来自患者的特异性肿瘤和MHC抗原。本发明还提供新的单核细胞衍生细胞，其可以在凋亡小体整合后用作抗肿瘤疫苗。细胞凋亡体被吞噬细胞并由单核细胞衍生的抗原呈递细胞处理，并增强免疫系统的有效肿瘤抗原呈递。

10. 发明授权

US06540994B1 Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions 失效
标题翻译：巨噬细胞，其制备方法及其作为药物组合物的活性物质的用途
公开(公告)号：US06540994B1
公开(公告)日：2003-04-01
申请号：US09304563
申请日：1999-05-04
申请人： Mohamed Chokri , Jacques Bartholeyns
发明人： Mohamed Chokri , Jacques Bartholeyns
IPC分类号： A61K4800
CPC分类号： C12N5/0645 , A61K2035/124 , C12N2500/38 , C12N2501/22 , C12N2501/24 , Y10S435/81
摘要： The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-7 is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-&ggr; is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-&ggr; is in a ratio such that after 60h of activation with IFN-&ggr;, the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-&ggr; activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.
摘要翻译：本发明涉及具有以下性质中的至少一个的巨噬细胞：其相对于标准巨噬细胞而言，其无IFN-7的细胞毒活性增加约20至30％，优选为约70％; 其与IFN-γ的细胞毒活性相对于标准巨噬细胞增加约20至约40％，优选为约93％; 与IFN-γ的激活相应的细胞毒活性的失活的延长是使得在用IFN-γ活化60小时后，细胞毒活性高于或等于30％，优选约55％，与由IFN-γ活化引起的巨噬细胞呈现的最大细胞毒活性相比，所述细胞毒活性被测量为目标肿瘤细胞，特别是U 937细胞的3-H胸苷掺入的抑制百分比。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式